ArticleArthritis & rheumatology (Hoboken, N.J.)2019
Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- FBXW7 mitigates hepatic fibrosis by degrading NOTCH1 to transcriptionally silence SEMA3G in liver sinusoidal endothelial cells.Nature communications · 2026Article
- Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers.Nature communications · 2026Article
- Diverse Roles of Semaphorins on T Cell Activation, Differentiation, Migration, and Effector Functions.Cells · 2026Review
- The microglia-derived protein Sema4ab attenuates regenerative neurogenesis after spinal cord injury in zebrafish.PLoS biology · 2026Article
- Sema4A Protects Against Muscle Atrophy and Promotes Repair by Regulating Intracellular Metabolic Signalling.Journal of cachexia, sarcopenia and muscle · 2026Article
- Spatially Distinct Macrophage Subsets Drive Myofibroblast Heterogeneity and Maladaptive Fibrosis in Lupus Nephritis.bioRxiv : the preprint server for biology · 2026Article
- Meningeal macrophages regulate fibroblasts to influence meningeal lymphatic function following traumatic brain injury.Theranostics · 2026Article
- SEMA4A signaling in macrophage subpopulations and its implication in osteoarthritis.Frontiers in immunology · 2026Article
- Inflammatory Semaphorins in the Pathogenesis and Prognosis of Acute Ischemic Stroke.Medicina (Kaunas, Lithuania) · 2025Article
- Chromatin interaction maps of human arterioles reveal mechanisms for the genetic regulation of blood pressure.Nature communications · 2025Article
- Semaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes.Arthritis research & therapy · 2025Article
- Semaphorin 3E-Plexin D1 Axis Drives Lung Fibrosis through ErbB2-Mediated Fibroblast Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis.eLife · 2024Article
- Single-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa.The Journal of clinical investigation · 2024Article
- Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers.International journal of molecular sciences · 2023Review
- ADAR1 promotes systemic sclerosisFrontiers in immunology · 2022Article
- Perspiration promotes the effect of sulphite on the shielding response of rodent skin.Heliyon · 2021Article
- Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.International journal of molecular sciences · 2020Review
- Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the potential role of semaphorin 4A (Sema4A) in inflammatory and fibrotic processes involved in the pathology of systemic sclerosis (SSc).
methodsSema4A levels in the plasma of healthy controls (n = 11) and SSc patients (n = 20) were determined by enzyme-linked immunosorbent assay (ELISA). The expression of Sema4A and its receptors in monocytes and CD4+ T cells from healthy controls and SSc patients (n = 6-7 per group) was determined by ELISA and flow cytometry. Th17 cytokine production by CD4+ T cells (n = 5-7) was analyzed by ELISA and flow cytometry. The production of inflammatory mediators and extracellular matrix (ECM) components by dermal fibroblast cells (n = 6) was analyzed by quantitative polymerase chain reaction, ELISA, Western blotting, confocal microscopy, and ECM deposition assay.
resultsPlasma levels of Sema4A, and Sema4A expression by circulating monocytes and CD4+ T cells, were significantly higher in SSc patients than in healthy controls (P < 0.05). Inflammatory mediators significantly up-regulated the secretion of Sema4A by monocytes and CD4+ T cells from SSc patients (P < 0.05 versus unstimulated SSc cells). Functional assays showed that Sema4A significantly enhanced the expression of Th17 cytokines induced by CD3/CD28 in total CD4+ T cells as well in different CD4+ T cell subsets (P < 0.05 versus unstimulated SSc cells). Finally, Sema4A induced a profibrotic phenotype in dermal fibroblasts from both healthy controls and SSc patients, which was abrogated by blocking or silencing the expression of Sema4A receptors.
conclusionOur findings indicate that Sema4A plays direct and dual roles in promoting inflammation and fibrosis, 2 main features of SSc, suggesting that Sema4A might be a novel therapeutic target in SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.